Twice a Year, Against Once Every Two Months
Both options in front of her are genuinely excellent by historical PrEP standards — the real disagreement is whether the newer drug's larger efficacy number should outweigh the older one's much longer track record, and whether either question matters as much as what her insurance will actually cover.
N.B., a 31-year-old woman, lives with her partner of the past year, a relationship she describes as serious despite not yet knowing his HIV status — something she's raised with him directly without a clear answer so far. She works as a flight attendant, a job that has her crossing time zones most weeks and, by her own account, made remembering a daily pill on a genuinely irregular schedule close to impossible during the year she tried oral PrEP. She stopped it after several months of inconsistent use and has been unprotected against HIV acquisition since. She came in today specifically asking about the long-acting injectable options she'd read about, having decided daily pills simply aren't realistic given her schedule, and says she's willing to plan her international layovers around whichever injection schedule the clinic recommends.
Two genuinely strong long-acting options are in front of her. Cabotegravir, dosed by injection every two months, has years of real-world use behind HPTN 083 and HPTN 084's original trial results, both of which found it superior to daily oral PrEP. Lenacapavir, approved more recently, offers an even less frequent schedule — twice yearly, after an oral lead-in — and its own pivotal trials set a new bar for PrEP efficacy: PURPOSE 1, in cisgender women in several African countries, recorded zero infections among participants receiving lenacapavir, and PURPOSE 2, in men and gender-diverse people who have sex with men, found comparably striking near-total protection. She has no chronic illness, no current medications, and her test today is negative. The choice in front of the team isn't between an effective option and an ineffective one — both are excellent — it's between a newer drug's larger trial number and an older one's longer track record, complicated further by which one her insurance will actually cover and by how well each schedule genuinely fits the specific rhythm of a job spent crossing time zones for a living.
PrEP clinic, new-patient consultation
Lenacapavir's trial results are genuinely remarkable — PURPOSE 1 recorded zero infections among participants on lenacapavir, and PURPOSE 2 found similarly near-total protection in a different population. Twice yearly is also the lowest visit burden of any option available, which matters directly for someone whose schedule made even a daily pill unworkable. I'd recommend lenacapavir.
I don't dispute those trial numbers at all — they're excellent.
But cabotegravir has years more real-world experience behind it now, through HPTN 083 and 084 and substantial post-marketing use since. That kind of accumulated real-world safety and adherence data, across a much larger and longer-followed population, is a different and genuinely valuable kind of evidence than a newly approved drug's trial results alone provide, however strong those results are. For a medication she may be on for years, I'd weigh that track record seriously, not just the newer number. And it's worth being precise about what actually failed her before: it was a daily pill, not a long-acting option at all. Cabotegravir every two months already solves the specific problem her history documents — we don't need the newest product to fix a failure mode neither of these two would have caused.
Both of those are real considerations, and honestly, for a lot of patients this decision gets made by a third factor before either of them: lenacapavir's insurance coverage is still inconsistent this soon after approval, while cabotegravir's coverage is generally well established at this point. An excellent option she can actually obtain reliably beats a marginally more efficacious one she might face a coverage gap on. I'd check her specific plan's coverage for both before finalizing this, rather than let the trial-number comparison decide it on its own.
Agreed: insurance coverage for lenacapavir will be verified this week, with cabotegravir started in the meantime as a bridging option if that verification takes longer than a few days, given her ongoing exposure risk shouldn't wait on an insurance call. Both options were presented to her directly as genuinely excellent, rather than framed as a clearly superior choice versus a clearly inferior one.